ACADIA Pharmaceuticals Stock Trading Halted Today
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Needham & Company Remains Bullish on Acadia Pharma (ACAD) Following Positive FDA Vote on Nuplazid
March 30, 2016 6:49 AM EDTNeedham & Company reiterated a Buy rating and $49.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following a vote by the FDA Psychopharmacologic Drugs Advisory Committee in favor of Nuplazid approval for treatment of Parkinson's Disease Psychosis. Committee members generally viewed Nuplazid as effective, with a few... More
Acadia Pharma (ACAD) Resumes Trading at 5:45 PM ET
March 29, 2016 5:43 PM EDTAcadia Pharma (NASDAQ: ACAD) Resumes Trading at 5:45 PM ET
... MoreAcadia Pharma (ACAD) Announces Favorable FDA Panel Vote on NUPLAZID for the Treatment of Psychosis Associated with Parkinson's Disease
March 29, 2016 5:14 PM EDTACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinsons disease outweigh the risks of... More
Acadia Pharma's (ACAD) NUPLAZID Seen Effective in Parkinson's - FDA Panel
March 29, 2016 2:55 PM EDTAcadia Pharma (NASDAQ: ACAD) received a positive FDA panel vote for pimavanserin in treating at least one disease. The following question was posed Tuesday:
1. VOTE: Has Acadia provided substantial evidence of effectiveness for NUPLAZID (pimavanserin) for the treatment of psychosis w/ PD?
12 panelists voted 'yes,' while 2 voted 'no.'
... MoreAcadia Pharma (ACAD) Said Facing 'Tough' Nuplazid Efficacy Questions from FDA Panel
March 29, 2016 10:14 AM EDTAcadia Pharma (NASDAQ: ACAD) is said to be facing tough questions on the efficacy of Nuplazid. The following was posted by pharma-watcher Adam Feuerstein to Twitter on Tuesday:
... More
